selinexor
selinexor: sourced relationships with 1 company · 35 clinical trials tracked · 1 FDA decision.
selinexor evidence translation
What we can confirm
1 FDA record · 35 tracked trials
What it means
What to watch
Prepared research question
How could selinexor → KPTI affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Karyopharm Therapeutics Inc. (KPTI) Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) | Approved |
Clinical Trial Registry Records (35)showing 10 most recent
Karyopharm Expanded Access Program for Selinexor
A Phase II Trial of Imlunestrant/Abemaciclib/Selinexor in Low Grade Serous Ovarian Cancer and in Endometrioid Endometrial Cancer
Primary endpoint: Objective Response Rate (ORR)
Phase Ib/II Study of Selinexor in Combination With Carfilzomib, Subcutaneous Isatuximab Administered Via Investigational Device and Dexamethasone (SCID) for Patients With Relapsed and/or Relapsed Refractory Multiple Myeloma
Primary endpoint: Adverse Events
Investigator-Initiated, Open-Label, Phase II Trial of Selinexor in Combination With Pacritinib in Patients With Myelofibrosis Who Are JAK Inhibitor-Naïve and Have Cytopenias (ILLUMINATE)
Primary endpoint: Change in spleen volume
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Primary endpoint: Rate of non-hematologic grade ≥ 3 treatment-related adverse events (excluding conditioning and CAR-T related adverse events) according to CTCAE v 6.0
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients: a Single-arm, Multicenter, Phase II Clinical Trial (Smart Trial)
Primary endpoint: Complete response rate (CRR)
A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma
Primary endpoint: Deep clinical response
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
Primary endpoint: Progression Free Survival (PFS)
Phase 1/2 Study of Selinexor With Dexamethasone, Ifosfamide, Carboplatin, and Etoposide in Patients Who Have Secondary Central Nervous System Involvement With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Primary endpoint: Maximum tolerated dose of elinexor in phase 1
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Primary endpoint: Proportion of Participants with Spleen Volume Reduction ≥35% (SVR35) at Week 24
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with selinexor?
selinexor has dated SEC/FDA relationship records for Karyopharm Therapeutics Inc..
How many clinical trials involve selinexor?
BioSniper tracks 35 clinical trials involving selinexor.
What is selinexor's latest FDA decision?
The most recent tracked FDA decision for selinexor is Approval for 1 INDICATIONS AND USAGE XPOVIO is a nuclear export inhibitor indicated: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy ( 1.1 ). In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody ( 1.1 ). 1.1 Multiple Myeloma XPOVIO in combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody., dated July 3, 2019.